Omalizumab biosimilar - Shanghai Zhangjiang BiotechnologyAlternative Names: Aomaishu; CMAB-007
Latest Information Update: 30 Dec 2015
At a glance
- Originator Shanghai Zhangjiang Biotechnology
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Allergic asthma
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 01 Dec 2015 Shanghai Zhangjiang Biotechnology completes a phase II/III trial in Allergic asthma (In adolescents, In adults) in China (NCT01976208)